132.48
price up icon0.67%   0.88
after-market Handel nachbörslich: 133.51 1.03 +0.78%
loading
Schlusskurs vom Vortag:
$131.60
Offen:
$130.93
24-Stunden-Volumen:
2.02M
Relative Volume:
1.78
Marktkapitalisierung:
$13.30B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$478.60M
KGV:
28.38
EPS:
4.6676
Netto-Cashflow:
$748.70M
1W Leistung:
+2.92%
1M Leistung:
+3.39%
6M Leistung:
-4.98%
1J Leistung:
+38.50%
1-Tages-Spanne:
Value
$125.31
$134.01
1-Wochen-Bereich:
Value
$125.31
$134.01
52-Wochen-Spanne:
Value
$84.23
$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Firmenname
Neurocrine Biosciences Inc
Name
Telefon
(858) 617-7600
Name
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Mitarbeiter
2,000
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
NBIX icon
NBIX
Neurocrine Biosciences Inc
132.48 13.21B 2.86B 478.60M 748.70M 4.6676
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.22 59.20B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
118.26 49.79B 9.47B 2.67B 2.28B 6.0218
HLN icon
HLN
Haleon Plc Adr
9.92 44.27B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
29.82 35.03B 17.41B 1.43B 1.00B 1.2182
UTHR icon
UTHR
United Therapeutics Corp
559.65 24.75B 3.18B 1.33B 1.04B 27.90

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-02-24 Eingeleitet Wolfe Research Outperform
2026-01-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-10-21 Eingeleitet Citigroup Buy
2025-07-21 Eingeleitet Truist Buy
2025-07-10 Eingeleitet Goldman Buy
2025-04-15 Hochstufung Needham Hold → Buy
2025-04-14 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2025-02-11 Eingeleitet Deutsche Bank Hold
2024-10-10 Fortgesetzt Raymond James Outperform
2024-08-29 Hochstufung Piper Sandler Neutral → Overweight
2024-04-24 Hochstufung Wells Fargo Equal Weight → Overweight
2023-12-13 Fortgesetzt Citigroup Neutral
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-08-21 Bestätigt Mizuho Neutral
2023-07-24 Hochstufung SVB Securities Market Perform → Outperform
2023-07-06 Hochstufung BMO Capital Markets Underperform → Market Perform
2023-05-04 Hochstufung Guggenheim Neutral → Buy
2023-03-30 Hochstufung Canaccord Genuity Hold → Buy
2023-03-03 Hochstufung Evercore ISI In-line → Outperform
2023-02-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-11-14 Herabstufung Evercore ISI Outperform → In-line
2022-10-11 Eingeleitet UBS Buy
2022-09-26 Eingeleitet Wells Fargo Equal Weight
2022-06-06 Fortgesetzt Jefferies Buy
2022-03-03 Herabstufung Piper Sandler Overweight → Neutral
2022-02-25 Hochstufung Goldman Neutral → Buy
2022-01-18 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Eingeleitet BMO Capital Markets Underperform
2021-11-17 Hochstufung JP Morgan Neutral → Overweight
2021-10-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-23 Fortgesetzt Needham Hold
2021-08-06 Herabstufung Canaccord Genuity Buy → Hold
2021-05-18 Fortgesetzt Goldman Neutral
2021-05-06 Hochstufung Barclays Equal Weight → Overweight
2021-02-02 Eingeleitet Raymond James Outperform
2020-09-30 Eingeleitet The Benchmark Company Hold
2020-08-04 Herabstufung JP Morgan Overweight → Neutral
2020-06-29 Herabstufung Goldman Buy → Neutral
2020-06-09 Eingeleitet Wedbush Outperform
2020-03-06 Eingeleitet Citigroup Buy
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-24 Eingeleitet William Blair Outperform
2020-02-06 Eingeleitet Mizuho Neutral
2020-02-05 Bestätigt H.C. Wainwright Buy
2019-12-13 Herabstufung Credit Suisse Outperform → Neutral
2019-08-07 Eingeleitet RBC Capital Mkts Outperform
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-05 Eingeleitet Guggenheim Neutral
2019-05-21 Eingeleitet Credit Suisse Outperform
2019-04-22 Hochstufung JP Morgan Neutral → Overweight
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-02-06 Bestätigt BofA/Merrill Buy
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-12-13 Eingeleitet Goldman Buy
2018-11-21 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten

pulisher
05:44 AM

Neurocrine’s $2.9B Soleno Buyout Brings What Could Become It’s Next Blockbuster Drug - MedCity News

05:44 AM
pulisher
05:23 AM

Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights

05:23 AM
pulisher
05:21 AM

This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals

05:21 AM
pulisher
05:08 AM

Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan

05:08 AM
pulisher
04:20 AM

Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool

04:20 AM
pulisher
04:05 AM

Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView

04:05 AM
pulisher
03:46 AM

Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus

03:46 AM
pulisher
02:50 AM

Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com

02:50 AM
pulisher
02:49 AM

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily

02:49 AM
pulisher
02:36 AM

Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's

02:36 AM
pulisher
02:29 AM

Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com

02:29 AM
pulisher
02:22 AM

Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia

02:22 AM
pulisher
01:47 AM

Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360

01:47 AM
pulisher
01:46 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today

01:46 AM
pulisher
01:22 AM

American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU

01:22 AM
pulisher
01:06 AM

Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance

01:06 AM
pulisher
01:06 AM

Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - marketbeat.com

01:06 AM
pulisher
12:10 PM

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - Yahoo Finance

12:10 PM
pulisher
12:00 PM

Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? - BioWorld MedTech

12:00 PM
pulisher
11:35 AM

Neurocrine Biosciences, Inc. entered into a definitive agreement to acquire Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others for $2.8 billion. - marketscreener.com

11:35 AM
pulisher
11:29 AM

Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug - inc.com

11:29 AM
pulisher
11:26 AM

Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal - MSN

11:26 AM
pulisher
11:09 AM

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1 - Minichart

11:09 AM
pulisher
11:07 AM

UBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.com - Investing.com South Africa

11:07 AM
pulisher
10:47 AM

Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder - WSJ

10:47 AM
pulisher
10:41 AM

Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com

10:41 AM
pulisher
10:34 AM

Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen - Stocktwits

10:34 AM
pulisher
10:33 AM

UBS reiterates Neurocrine Bio stock rating on acquisition news - investing.com

10:33 AM
pulisher
10:32 AM

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout - BioPharma Dive

10:32 AM
pulisher
10:25 AM

Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios

10:25 AM
pulisher
10:05 AM

Quarterly Trades: Is Neurocrine Biosciences Inc stock technically oversold2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn

10:05 AM
pulisher
09:53 AM

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters

09:53 AM
pulisher
09:45 AM

Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com

09:45 AM
pulisher
09:35 AM

Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo! Finance Canada

09:35 AM
pulisher
09:31 AM

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion - MLex

09:31 AM
pulisher
09:12 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com

09:12 AM
pulisher
09:08 AM

Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - MEXC

09:08 AM
pulisher
09:03 AM

Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - contractpharma.com

09:03 AM
pulisher
08:13 AM

Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketNeurocrine Biosciences (NASDAQ:NBIX), Sol - Benzinga

08:13 AM
pulisher
08:10 AM

According to the latest disclosed agreement terms, if the acquisition is terminated under specific circumstances, Soleno Therapeutics (SLNO) will be required to pay Neurocrine Biosciences (NBIX) a termination fee of up to 953 millions dollars. - Bitget

08:10 AM
pulisher
08:01 AM

Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - TipRanks

08:01 AM
pulisher
07:54 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com

07:54 AM
pulisher
07:53 AM

Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView

07:53 AM
pulisher
07:50 AM

Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan

07:50 AM
pulisher
07:46 AM

Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan

07:46 AM
pulisher
07:43 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics in $53-Per-Share Tender Offer and Merger - TradingView

07:43 AM
pulisher
07:40 AM

Neurocrine Biosciences Inc if deal terminated under some circumstances Soleno will pay co termination fee of $95.3 million - marketscreener.com

07:40 AM
pulisher
07:39 AM

Neurocrine Biosciences Inc If Deal Terminated Under Some Circumstances Soleno Will Pay Co Termination Fee Of $95.3 Million - TradingView

07:39 AM
pulisher
07:35 AM

Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan

07:35 AM
pulisher
07:34 AM

Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final) - marketscreener.com

07:34 AM
pulisher
07:24 AM

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barron's

07:24 AM

Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
ABERNETHY MATT
Chief Financial Officer
Feb 12 '26
Option Exercise
0.00
2,133
0
39,230
Boyer David W.
Chief Corp. Affairs Officer
Feb 13 '26
Option Exercise
0.00
3,352
0
7,969
Boyer David W.
Chief Corp. Affairs Officer
Feb 12 '26
Option Exercise
0.00
1,600
0
6,313
Gano Kyle
Chief Executive Officer
Feb 13 '26
Option Exercise
0.00
4,807
0
147,610
Gano Kyle
Chief Executive Officer
Feb 12 '26
Option Exercise
0.00
4,907
0
146,661
Onyia Jude
Chief Scientific Officer
Feb 13 '26
Option Exercise
0.00
5,407
0
21,066
Onyia Jude
Chief Scientific Officer
Feb 12 '26
Option Exercise
0.00
2,560
0
18,537
BENEVICH ERIC
Chief Commercial Officer
Feb 13 '26
Option Exercise
0.00
4,044
0
56,664
BENEVICH ERIC
Chief Commercial Officer
Feb 12 '26
Option Exercise
0.00
2,005
0
54,760
Cooke Julie
Chief Human Resources Officer
Feb 13 '26
Option Exercise
0.00
2,911
0
30,395
RGC RGC
$30.83
price up icon 0.10%
$22.82
price down icon 1.13%
$13.41
price down icon 0.22%
RDY RDY
$13.14
price down icon 1.35%
$559.65
price down icon 0.91%
Kapitalisierung:     |  Volumen (24h):